Similar articles

• Dosing Strategies of Bone-Targeting Agents.

  Uzoigwe CE. Uzoigwe CE. JAMA Intern Med. 2015 Nov;175(11):1865. doi: 10.1001/jamainternmed.2015.4796. JAMA Intern Med. 2015. PMID: 26524745 No abstract available.
• Dosing Strategies of Bone-Targeting Agents.

  Hutton B, Mazzarello S, Clemons M. Hutton B, et al. JAMA Intern Med. 2015 Nov;175(11):1864-5. doi: 10.1001/jamainternmed.2015.4789. JAMA Intern Med. 2015. PMID: 26524744 No abstract available.
• A once-yearly IV bisphosphonate for osteoporosis.

  [No authors listed] [No authors listed] Obstet Gynecol. 2008 May;111(5):1208-9. doi: 10.1097/01.AOG.0000313748.64874.e8. Obstet Gynecol. 2008. PMID: 18448761 No abstract available.
• [New bone density conservation agents for osteoporosis under research and development: Zoledronate].

  Wada S, Fukawa T, Kamiya S. Wada S, et al. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:421-5. Nihon Rinsho. 2007. PMID: 18161143 Review. Japanese. No abstract available.
• [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].

  Tanaka M, Mori H, Shimizu K, Toshiyuki, Matsuoka, Yamamotoya H, Minamide T, Mori M, Nozaki K, Usui T, Shimokawa K, Suzuki H, Aoyama K, Kimoto A, Sasamata M, Miyata K. Tanaka M, et al. Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. doi: 10.1254/fpj.134.149. Nihon Yakurigaku Zasshi. 2009. PMID: 19749488 Review. Japanese. No abstract available.